ESR2 and medulloblastoma: Recent studies showed that selective targeting of ERβ with agonists can sensitize malignant pleural mesothelial cells to cisplatin toxicity19 and that inhibition of ERβ increased DNA repair that contributes to cisplatin resistance in medulloblastoma cells47.